A Phase 1 interventional study of AUBE00 and Cetuximab in Solid Tumors, sponsored by Chugai Pharmaceutical. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.
Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive AUBE00 as an oral administration at escalated doses. Patients may also receive prophylactic management for treatment-related adverse events.
Drug: AUBE00
Patients will receive AUBE00 as an oral administration at multiple dose levels determined to be safe (including MTD).
Drug: AUBE00
Patients will receive AUBE00 as an oral administration in combination with cetuximab as an IV infusion at escalated doses or the recommended dose level.
Drug: AUBE00 · Drug: Cetuximab
AUBE00 as an oral administration
Cetuximab as an IV infusion
Adverse events of AUBE00 [Part A, B, C]
Incidence, nature, and severity of adverse events (AEs), with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Number of participants with changes in vital signs of AUBE00 [Part A, B, C]
Change from baseline in vital signs (Includes respiratory rate, pulse oximetry, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated or semi-recumbent position, and temperature.)
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Number of participants with changes in clinical laboratory test of AUBE00 [Part A, B, C]
Change from baseline in clinical laboratory test
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Number of participants with changes in Electrocardiograms (ECGs) of AUBE00 [Part A, B, C]
Change from baseline in ECGs (QT interval)
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Maximum tolerated dose (MTD) of AUBE00 [Part A, C]
Incidence and nature of dose-limiting toxicities (DLTs)
Time frame: From Cycle 0 Day 1 until Cycle 2 Day 1 (approximately 30 days) (Cycle 0: 6 to 9 days, Cycle 1 and beyond each Cycle: 21 days) [Part A]; From Cycle 1 Day 1 until Cycle 2 Day 1 (approximately 28 days) (Cycle 1 and beyond each Cycle: 28 days) [Part C]
Time to reach maximum plasma concentration (Tmax) of AUBE00 [Part A]
Tmax of AUBE00
Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)
Maximum plasma concentration (Cmax) of AUBE00 [Part A]
Cmax of AUBE00
Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)
Elimination half-life (t1/2) of AUBE00 [Part A]
t1/2 of AUBE00
Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)
Area under the plasma concentration-time curve (AUC) of AUBE00 [Part A]
AUC of AUBE00
Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)
Objective response of AUBE00 [Part B, C]
Objective response, defined as a confirmed complete response (CR) or partial response (PR) as the best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the Investigator
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Objective response of AUBE00 [Part A]
Objective response, defined as a confirmed CR or PR as the best overall response per RECIST v1.1 as determined by the Investigator
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Disease control of AUBE00 [Part A, B, C]
Disease control, defined as a confirmed CR, PR, or stable disease (SD) per RECIST v1.1 as determined by the Investigator
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Duration of response (DoR) of AUBE00 [Part A, B, C]
DoR, defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression per RECIST v1.1 as determined by the Investigator or death due to any cause, whichever occurs first
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Progression free survival (PFS) of AUBE00 [Part A, B, C]
PFS, defined as the time from the first study treatment to the first occurrence of disease progression per RECIST v1.1 as determined by the Investigator or death due to any cause, whichever occurs first
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Anti-AUBE00 antibodies of AUBE00 [Part A, B, C]
Incidence of anti-AUBE00 antibodies
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Overall survival (OS) of AUBE00 [Part B, C]
OS, defined as the time from the date of first study treatment to death due to any cause
Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)
Time to reach maximum plasma concentration (Tmax) of AUBE00 [Part B, C]
Tmax of AUBE00
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Maximum plasma concentration (Cmax) of AUBE00 [Part B, C]
Cmax of AUBE00
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Elimination half-life (t1/2) of AUBE00 [Part B, C]
t1/2 of AUBE00
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)[Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Area under the plasma concentration-time curve (AUC) of AUBE00 [Part B, C]
AUC of AUBE00
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)[Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Time to reach maximum serum concentration (Tmax) of cetuximab [Part C]
Tmax of cetuximab
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Maximum serum concentration (Cmax) of cetuximab [Part C]
Cmax of cetuximab
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Elimination half-life (t1/2) of cetuximab [Part C]
t1/2 of cetuximab
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Area under the serum concentration-time curve (AUC) of cetuximab [Part C]
AUC of cetuximab
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Anti-cetuximab antibodies of cetuximab [Part C]
Incidence of anti-cetuximab antibodies
Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2029, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.